(Q38027330)

1 July 2019

title

Personalized treatment of alcohol dependence (English)

1 reference

1 July 2019

1

Henry R Kranzler

1 reference

1 July 2019

author name string

James R McKay

series ordinal

2

1 reference

1 July 2019

language of work or name

English

0 references

publication date

1 October 2012

1 reference

1 July 2019

Current Psychiatry Reports

published in

1 reference

1 July 2019

volume

14

1 reference

1 July 2019

issue

5

1 reference

1 July 2019

page(s)

486-493

1 reference

1 July 2019

The Path to Personalized Medicine

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

The case for routine genotyping in dual-antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

A conceptual framework for adaptive preventive interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

The contribution of genetics to addiction therapy approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

The mu opioid receptor: from molecular cloning to functional studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Mu opioid receptor gene variants: lack of association with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Genetic moderators of naltrexone's effects on alcohol cue reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Predicting treatment response to naltrexone: the influence of craving and family history

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Serotonin and alcohol intake, abuse, and dependence: clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Medications acting on the serotonergic system for the treatment of alcohol dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Allelic Variation of Human Serotonin Transporter Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Evaluation of a telephone-based stepped care intervention for alcohol-related disorders: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

The effectiveness of telephone-based continuing care for alcohol and cocaine dependence: 24-month outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Do patient characteristics and initial progress in treatment moderate the effectiveness of telephone-based continuing care for substance use disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Extended telephone-based continuing care for alcohol dependence: 24-month outcomes and subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

The effect of matching comprehensive services to patients' needs on drug use improvement in addiction treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Using behavioral reinforcement to improve methadone treatment participation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

A multicenter randomized evaluation of methadone medical maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Combining stepped-care approaches with behavioral reinforcement to motivate employment in opioid-dependent outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Adaptive Interventions in Drug Court: A Pilot Experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Genetics of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0296-5

Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment

21 January 2018

1 reference

12 December 2020

A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.

1 reference

12 December 2020

Allelic variation of human serotonin transporter gene expression

1 reference

12 December 2020

Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype

1 reference

12 December 2020

Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study

1 reference

12 December 2020

Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial

1 reference

12 December 2020

Continuing care for cocaine dependence: comprehensive 2-year outcomes

1 reference

12 December 2020

Personalized medicine in psychiatry: ethical challenges and opportunities.

1 reference

12 December 2020

Fluoxetine Treatment Seems to Reduce the Beneficial Effects of Cognitive-Behavioral Therapy in Type B Alcoholics

1 reference

12 December 2020

Naltrexone in the treatment of alcohol dependence

1 reference

12 December 2020

Reminder letter, tailored stepped-care, and self-choice comparison for repeat mammography

1 reference

12 December 2020

10.1007/S11920-012-0296-5

Identifiers

DOI

1 reference

1 July 2019

Dimensions Publication ID

0 references

1 reference

1 July 2019

PubMed publication ID

22810115

1 reference

1 July 2019